Isracann Biosciences Inc. (OTC:ISCNF) (CSE:IPOT) Aiming To Disrupt The $100 Billion Cannabis Market With Its Ultra-Low Production Cost


"How Startup Nation Could Make Medical Marijuana 'The Next Coca Cola'" - Haaretz News, Israel (Mar 27, 2019)

Top 5 Reasons To Put Isracann Biosciences Inc. (OTC:ISCNF) (CSE:IPOT) On Your Watchlist Today

  • Led by a management team with proven record of success in the cannabis sector, Isracann Biosciences Inc. (OTC:ISCNF) (CSE:IPOT) will be Israel’s first pure-play cannabis company listed on the CSE.
  • Israel's government approved exports in January 2019 - The export framework is expected to be fully operational by Q2-2020, which could open access to Europes burgeoning marketplace.
  • Israel has a renowned reputation as a leader in cannabis research; customers can be assured of only the highest quality product.
  • Optimal climatic conditions allow for industry-leading production costs of grown medical cannabis.
  • The company has received Land Use and Facility Approvals from Israeli Land Authority and has commenced its fully funded Phase One development plans for 230,000 square foot cultivation facilities capable of producing up to 23,500kg/year.

Reevaluating Cannabis Stocks - Choose Wisely For Outsized Gains

Cannabis stocks posted exceptional returns in 2018 but the sector failed to maintain this momentum in 2019.  Over the past couple of months, pot stocks have taken a hit which has spooked some investors.

Both the Horizons Marijuana Life Sciences ETF and the Marijuana Index, which tracks the top North American cannabis companies fell roughly 50 percent in the last six months, forcing a number of analysts to turn bearish on the sector.

However, one thing has been made very clear. Risk tolerant investors willing to go against the herd mentality by investing in lesser known names have been rewarded handsomely while those who bet on mainstream names have been crushed.

For instance, if you had invested in the cannabis extraction company MediPharm Labs (OTC: MEDIF) or cannabis focused REIT Innovative Industrial Properties (NYSE: IIPR) at the beginning of the year, you could have doubled your money by now.

On the other hand, if you had invested in two of the largest Canadian growers Canopy Growth (NYSE: CGC) or Aurora Cannabis (NASDAQ: ACB) you would be down roughly 20 percent over the same time period.

(Source: Yahoo! Finance)

At the moment, it appears that the market has realized that most mainstream cannabis stocks have grown too rich in valuation as more investors have poured into the trade, resulting in a dire need for a correction.

As volatility continues to rock the sector, it is important for investors to remember that North American companies aren’t the only way to play the cannabis opportunity.

Never Miss An Update From Isracann Biosciences Inc

Isracann BioSciences Logo Pantones@2x MED

Subscribe For Updates From Isracann Biosciences INC.

* indicates required

By subscribing you agree to Hot Stocks Reviews Terms and Conditions

Isracann Biosciences Inc. (OTC:ISCNF) (CSE:IPOT) - "An Emerging World Leader In Low Cost Cannabis Production"

A growing legalized cannabis market in Europe that is poised to quickly surpass America’s is ripe for the taking and there is a great way for investors to uniquely capitalize on this opportunity.

Canadian based, Israeli operated Isracann Biosciences Inc. (OTC:ISCNF) (CSE:IPOT) has just gone public, listing their shares on the Canadian Stock Exchange, presenting a great way to gain exposure to the under-supplied domestic market, as well as the burgeoning European cannabis market.

Although some investors may be wondering what the European cannabis market and an Israeli company have to do with each other, here is what you need to know.

In late December last year, the Israeli Parliament passed the 16th amendment to Dangerous Drugs Ordinance that concerns the governance and regulatory aspects of exporting medical cannabis from Israel.

This legislation allows licensed entities approved by the health regulator and police to export medical cannabis to countries that permit its use, thus propelling Israel to the elite club of only three countries in the world allowing cannabis exports.

Isracann Biosciences Inc. (OTC:ISCNF) (CSE:IPOT), focused on becoming a premiere cannabis company, and will be well positioned to export low-cost, high quality product to the EU medical market with Germany as a starting point.

They are offering investors a unique, ground floor opportunity in a little known cannabis stock that could deliver out-sized, near term gains.

A massive opportunity that could turn Isracann Biosciences Inc. (OTC:ISCNF) (CSE:IPOT) into a portfolio winner.

According to Grand View Research, the global cannabis industry is projected to be worth nearly $150 billion by 2025.  Rapid growth will be driven by the liberalization of cannabis laws throughout Europe - a report titled ‘The European Cannabis Report’ published by researchers at Prohibition Partners predicts that Europe is set to become the world’s largest legal cannabis market in the next five years and could be worth as much as €123 billion by 2028.

Medical cannabis is already available in 10 European countries, and given Europe’s population of 740 million (approx. double USA and Canada), the opportunity to capitalize is clear.  Germany’s medical market is potentially larger than the rest of Europe combined, hence the company’s intention to start there.

With such encouraging growth prospects, it’s no surprise that Isracann Biosciences Inc. (OTC:ISCNF) (CSE:IPOT) is angling for a piece of this immense market.

Darryl Jones, President of Isracann Biosciences Inc. (OTC:ISCNF) (CSE:IPOT) notes in a September 26 news release, “Today’s announcement is an important milestone that will accelerate activities as we move forward in the execution on our strategic plan. As announced in May, the Company already closed its highly successful CAD$10.1 million financing efforts which bolstered an already healthy cash position. Now that we have the conditional approval to conclude the Transaction and subsequent public listing, we are ready to commence Isracann’s proposed Phase I facility of 230,000 square feet of cultivation area and additional strategic goals. With Israel’s recently adopted export legislation we look forward to working towards a leading role in the development of both the domestic and underserved European consumer markets.”

How Does Isracann Biosciences Inc. (OTC:ISCNF) (CSE:IPOT) Stack Up Against the Competition?

The table below demonstrates how Isracann Biosciences Inc. (OTC:ISCNF) (CSE:IPOT) could disrupt the broader cannabis industry and deliver sustainable returns for shareholders.

When comparing enterprise value among its peers, it's easy to see the potential for re-valuation on the upside, especially given the company's advantage in jurisdiction, proximity to Europe and optimal climatic conditions for growing.

Additionally, although the yield per square foot is roughly the same across all growers (approximately 100g), Isracann Biosciences Inc. (OTC:ISCNF) (CSE:IPOT) is expected to operate at a higher efficiency, extremely low cost and produce one of the highest margins in the industry.  This key metric should further enable Isracann Biosciences Inc. (OTC:ISCNF) (CSE:IPOT) to eventually command a much better valuation relative to peers.

Israel – Optimal Base of Operations

* Image for illustration purposes only

Pioneers in Cannabis Research

  • History of cannabis innovation and research with THC and CBD cannabinoid structure discovered at Hebrew University of Jerusalem.
  • Access to top researchers in the field provides valuable strategic data for the development of formulations and cannabinoid profiles.
  • 10,000 patients on waitlist for medical cannabis due to supply constraints.
  • Patients expected to exceed 50,000 in 2019.

Optimal Climatic Conditions



Low-cost Operations
Optimal climate and infrastructure allow for greenhouses and low-cost production of approx. $0.40/gram.


Leading Research Centre
Researchers in Israel have been studying cannabis for 50 years.


Agricultural Innovation
Israel is world renowned as an agricultural innovation hub.


Leading Partnerships
Partnership with leading Israeli research institutions and Universities to leverage their expertise and bring novel products to market

Never Miss An Update From Isracann

Isracann BioSciences Logo Pantones@2x MED

Subscribe For Updates From Isracann Biosciences INC.

* indicates required

By subscribing you agree to Hot Stocks Reviews Terms and Conditions

Seasoned and Proven Management

No matter how sound a business model is, it’s worth little without competent leadership to steer it to its full potential.

Isracann Biosciences Inc. (OTC:ISCNF) (CSE:IPOT) has assembled an exceptional management team with a proven record of success in capital markets and the international cannabis industry.

The company is led by President & CEO Darryl Jones, who has over 15 years of capital market experience with a well-established financial network.  Prior to joining Isracann Biosciences Inc. (OTC:ISCNF) (CSE:IPOT) in 2018, Mr. Jones was an investment advisor with PI Financial Corp Canada, where he raised seed capital and took True Leaf Medicine (CSE: MJ/OTC: TRLFF) public in early 2014 at a $10MM valuation and exited in 2016 at $150MM market capitalization.

The COO, Israel Moseson has been involved in the cannabis sector for over 5 years in Israel and is responsible for in-country operations.  Prior to entering the cannabis industry, Mr. Moseson specialized in financing Israeli and African companies.

The impressive opportunity presented by Isracann Biosciences Inc. (OTC:ISCNF) (CSE:IPOT) has also attracted an Advisory Board worthy of mention here:

Brett Allan has over 10 years of investment and capital markets experience and is currently founder, President and CEO of Apex Capital, which provides IR, PR and corporate finance services to publicly traded companies. Mr. Allan has assisted in raising $400MM in the cannabis sector as the VP of Corporate Development for Organigram (OGI:TSXV), founding member of Emblem Health (EMC:TSXV), and founding member of The Green Organic Dutchman (TGOD:TSX). Mr. Allen has a deep network in the cannabis markets with a specific orientation towards international cannabis companies and exportation.

Mathew Christopherson has over 10 years of experience within the cannabis space. Previously he was VP of Business Development and a Partner at Keirton Inc., a company that provides growers with medical cannabis harvesting machines under the brand “Twister Trimmer”. In addition, Mr. Christopherson is a co-founder of Lift & Co, Canada’s largest cannabis education and tech platform powered by the industry’s largest database of medical marijuana and strain reviews left by real medical cannabis patients. Furthermore, he has worked with over 100 LP’s in Canada and all original 8 LP’s in Israel over the last 7 years. Throughout his career, Mr. Christopherson has visited over 2,000 cannabis cultivation facilities, both domestically and internationally. Currently, Mr. Christopherson is the co-founder, president and chief executive officer of Higharchy Cannabis Group, a consortium of companies focused on consumer brands and retail experience in the cannabis sector.

Justin Cooper is Co-Owner of Green Planet Wholesale, the largest privately owned hydroponics chain in Canada. For +25 years he has built manufacturing, wholesale, & retail locations servicing some of the biggest growers in the world. Currently supplying products to over 50 licensed producers (LPs).

Investment Summary - Why Investors Are Buzzing Over Isracann Biosciences Inc. (OTC:ISCNF) (CSE:IPOT)


"Israel is banking on cannabis as its next big industry."
- L.A. Times (May 29, 2019)

Newly listed Isracann Biosciences Inc. (OTC:ISCNF) (CSE:IPOT) is fully funded to commence construction of a 230,000 square foot facility, and has access to Europe’s burgeoning medical cannabis sector.  Israel’s optimal growing conditions will allow for low-cost cultivation and production of high quality product.  Led by an exceptionally talented management team, the Company intends to become a key industrial-scale player not only within Israel’s under-supplied market, but throughout Europe, starting with Germany’s huge marketplace.

*** Updates ***

November has been a good month for Isracann Biosciences Inc (OTC:ISCNF) (CSE:IPOT). There has been a stream of positive developments from both the corporate and regulatory front which has further reinforced our thesis on the company’s future prospects.

First, Isracann (OTC:ISCNF) (CSE:IPOT) announced the engagement of two leading consultancies within the early-stage Israeli cannabis sector, to advance architectural and security plans for their 230,000 square foot facility.

To this end Isracann (OTC:ISCNF) (CSE:IPOT) contracted AgroPlan Ltd. -- an architectural company, to come up with architectural designs for the grow/harvest facility. AgroPlan provides engineering, architectural and project management support with a specific focus on farm and ranch facilities. The company regularly works with the Ministry of Agriculture and the Ministry of Environmental Protection and has so far completed over 15 cannabis farm projects both domestically and internationally.

Engaging AgroPlan puts Isracann (OTC:ISCNF) (CSE:IPOT) on the enviable path toward obtaining the coveted IMC-GAP, Israeli Medical Cannabis – Good Agricultural Practices code certification (Yakar Directive 151) and IMC-GMP, Israeli Medical Cannabis – Good Manufacturing Practices code certification (Yakar Directive 152).

On the security front, Isracann (OTC:ISCNF) (CSE:IPOT) hired A.R. Factor Group which currently provides security design services to over a dozen regional licensed producers. Its main role will be to prepare the security design of the cultivation and harvest facilities and provide critical input to ensure the company’s architectural plans are suitable for and compliant with IMC-GSP, Israeli Medical Cannabis – Good Security Practices code (Yakar Directive 150).

Secondly, Isracann (OTC:ISCNF) (CSE:IPOT) engaged LinC by Growing Smart Ltd. to deliver a formal project characterization roadmap for the successful development of its proposed 230,000 sq. ft. grow/harvest facility. LinC has over 20 years direct experience successfully serving the medical cannabis industry in Israel and abroad and will play and additional role as the provider of agronomic services.

Lastly and what we consider will translate to a major tailwind for Isracann (OTC:ISCNF) (CSE:IPOT) is the Ministry of Health’s decision to issue cannabis export guidelines on Monday, November 18. According to a statement to the high court from Israel’s Ministry of Health, any business that meets the standard for local production and marketing could also market the products overseas.

Combined, these developments provide Isracann Bioscinces Inc (OTC:ISCNF) (CSE:IPOT) with impetus required to deliver on it’s goal to supply not only an undersupplied local market in Israel, but the burgeoning multi-billion dollar medical cannabis market throughout Europe.


Never Miss An Update From Isracann

Isracann BioSciences Logo Pantones@2x MED

Subscribe For Updates From Isracann Biosciences INC.

* indicates required

By subscribing you agree to Hot Stocks Reviews Terms and Conditions




While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter/report/commentary piece/article is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Furthermore, it is certainly possible for errors or omissions to take place regarding the profiled company, in communications, writing and/or editing.

Nothing in this publication should be considered as personalized financial advice. We are not licensed under any securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. The information provided in this article is for informational purposes only and is not a recommendation to buy or sell any security. Please consult a licensed financial advisor before making any investment decision. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. is a website owned by Mountain Capital Corp (“Mountain”). Mountain has received $50,000 USD from Isracann Biosciences Inc. for the purpose of preparing, hosting and advertising this content for a period of 30 campaign days. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision.

By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing Mountain Capital Corp, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

Please refer to our complete Disclaimer and Disclosure here